Biomea Fusion Inc. (BMEA)
| Bid | 3.65 |
| Market Cap | 133.00M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.01 |
| PE Ratio (ttm) | -0.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.73 |
| Volume | 213,304 |
| Avg. Volume (20D) | 783,342 |
| Open | 3.56 |
| Previous Close | 3.57 |
| Day's Range | 3.52 - 3.75 |
| 52-Week Range | 3.25 - 19.36 |
| Beta | undefined |
About BMEA
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redw...
Analyst Forecast
According to 12 analyst ratings, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 499.46% from the latest price.
2 months ago · https://thefly.com
Biomea's icovamenib meets HbA1c standards in T2D, says H.C. WainwrightBiomea on Tuesday announced positive topline results from its Phase 2 COVALENT-111 trial evaluating icovamenib in patients with type 2 diabetes, with key takeaways including icovamenib displaying a st...
